Ruiz-Saenz, Ana http://orcid.org/0000-0001-6033-6153
Atreya, Chloe E.
Wang, Changjun
Pan, Bo http://orcid.org/0000-0001-7547-1470
Dreyer, Courtney A.
Brunen, Diede
Prahallad, Anirudh
Muñoz, Denise P.
Ramms, Dana J. http://orcid.org/0000-0002-7700-1728
Burghi, Valeria
Spassov, Danislav S. http://orcid.org/0000-0002-6680-877X
Fewings, Eleanor
Hwang, Yeonjoo C. http://orcid.org/0000-0002-3000-4710
Cowdrey, Cynthia
Moelders, Christina
Schwarzer, Cecilia
Wolf, Denise M.
Hann, Byron
VandenBerg, Scott R.
Shokat, Kevan http://orcid.org/0000-0001-8590-7741
Moasser, Mark M. http://orcid.org/0000-0003-4411-4336
Bernards, René http://orcid.org/0000-0001-8677-3423
Gutkind, J. Silvio http://orcid.org/0000-0002-5150-4482
van ‘t Veer, Laura J. http://orcid.org/0000-0002-9838-8298
Coppé, Jean-Philippe http://orcid.org/0000-0002-0890-8326
Article History
Received: 21 March 2021
Accepted: 21 December 2022
First Online: 9 February 2023
Competing interests
: C.E.A. served on the scientific advisory boards of Array Biopharma, Pfizer and Pionyr Immunotherapeutics and has received research funding (institutional) from Bristol Meyers Squibb, Erasca, Guardant Health, Kura Oncology, Merck and Novartis. The remaining authors declare no competing interests.